916483-51-7

Basic information

• Product Name: 2-chloro-N-(2,3-difluorophenyl)acetamide
• Synonyms: 2-chloro-N-(2,3-difluorophenyl)acetamide
• CAS NO: 916483-51-7
• Molecular Weight: 205.592
• Mol File: 916483-51-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-chloro-N-(2,3-difluorophenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-N-(2,3-difluorophenyl)acetamide(916483-51-7)
• EPA Substance Registry System: 2-chloro-N-(2,3-difluorophenyl)acetamide(916483-51-7)

Safety Data

• Hazardous Substances Data: 916483-51-7(Hazardous Substances Data)

Upstream product

• 4519-40-8 2,3-difluoroanilline 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 916483-55-1 tert-butyl (2R)-2-[({4-[(1-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-4-yl)amino]-7-ethoxyquinazolin-5-yl}oxy)methyl]pyrrolidine-1-carboxylate hydrochloride 
• 916483-48-2 N-(2,3-difluorophenyl)-2-{4-[(7-ethoxy-5-methoxyquinazolin-4-yl)amino]-1H-pyrazol-1-yl}acetamide hydrochloride 
• 916483-47-1 tert-butyl (2R)-2-[({4-[(1-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-4-yl)amino]-7-ethoxyquinazolin-5-yl}oxy)methyl]pyrrolidine-1-carboxylate 
• 916483-50-6 N-(2,3-difluorophenyl)-2-{4-[(7-ethoxy-5-hydroxyquinazolin-4-yl)amino]-1H-pyrazol-1-yl}acetamide 
• 916483-53-9 N-(2,3-difluorophenyl)-2-{4-[(diphenylmethylene)amino]-1H-pyrazol-1-yl}acetamide 
• 786681-68-3 2-(4-amino-1H-pyrazol-1-yl)-N-(2,3-difluorophenyl)acetamide 
• 916483-52-8 2-(4-bromo-1H-pyrazol-1-yl)-N-(2,3-difluorophenyl)acetamide 

Relevant articles and documents

Synthesis and Biological Evaluation of Dithiobisacetamides as Novel Urease Inhibitors

Thirty-eight disulfides containing N-arylacetamide were designed and synthesized in an effort to develop novel urease inhibitors. Biological evaluation revealed that some of the synthetic compounds exhibited strong inhibitory potency against both cell-free urease and urease in intact cell with low cytotoxicity to mammalian cells even at concentration up to 250 μM. Of note, 2,2′-dithiobis(N-(2-fluorophenyl)acetamide) (d7), 2,2′-dithiobis(N-(3,5-difluorophenyl)acetamide) (d24), and 2,2′-dithiobis(N-(3-fluorophenyl)acetamide) (d8) were here identified as the most active inhibitors with IC50 of 0.074, 0.44, and 0.81 μM, showing 32- to 355-fold higher potency than the positive control acetohydroxamic acid. These disulfides were confirmed to bind urease without covalent modification of the cysteine residue and to inhibit urease reversibly with a mixed inhibition mechanism. They also showed very good anti-Helicobacter pylori activities with d8 showing a comparable potency to the clinical used drug amoxicillin. The impressive in vitro biological profile indicated their immense potential as therapeutic agents to tackle H. pylori caused infections.

Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics

Small molecule choline kinase inhibitors having the following formula: are provided herein. Also provided herein are pharmaceutical compositions containing Formula I compounds, together with methods of treating cancer, methods of inhibiting choline kinase enzymatic activity, and methods of treating tumors by administering an effective amount of a Formula I compound.

QUINAZOLINES AND THEIR USE AS AURORA KINASE INHIBITORS

The invention provided a compound of formula (I) for use in the treatment of disease, in particular proliferative diseases such as cancer and for use in the preparation of medicaments for use in the treatment of proliferative diseases; the invention also